| drug name | Montelukast |
| classification | Leukotriene Receptor Antagonist (LTRA) |
| pharmacokinetics | Oral administration; rapidly absorbed; primarily metabolized in the liver; elimination half-life is approximately 3-10 hours. Plasma protein binding is approximately 99%. |
| dosage | | adult 70kg | 10mg PO once daily |
|
| indications | | 1 | Prevention and treatment of asthma, especially in patients with allergic triggers. | | 2 | Treatment of chronic urticaria and angioedema. | | 3 | Prevention of exercise-induced bronchospasm. |
|
| safety pregnancy | Limited data, use with caution. Consult a healthcare professional. |
| safety breastfeeding | Limited data; possible excretion in breast milk. Consult a healthcare professional. |
| side effects | | 1 | Headache | | 2 | Nasopharyngitis | | 3 | Gastrointestinal upset (abdominal pain, nausea, vomiting) | | 4 | Fatigue | | 5 | Skin rash | | 6 | Increased liver enzymes (rare) | | 7 | Rarely, serious allergic reactions |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to montelukast or any of its components. |
|
| interactions | | 1 | CYP2C8 substrates (e.g., warfarin) - monitor for potential interactions. | | 2 | Alcohol - may increase risk of side effects, avoid excessive intake. |
|
| warnings and precautions | | 1 | Monitor for worsening asthma symptoms, especially during the initial phase of treatment. | | 2 | May cause drowsiness or dizziness. Caution when operating machinery or driving. | | 3 | Use with caution in patients with liver disease. |
|
| additional information | Often used in combination with inhaled corticosteroids (ICS), especially LABAs (long-acting beta-agonists) in asthma management for enhanced symptom control. A physician should determine the specific treatment regimen. |
| patient details | |
